title_logo menu_logo
twitter
menu_bg
Pilot & Feasibility Data Search



ABOUT THE DIABETIC COMPLICATIONS CONSORTIUM (DiaComp):

The goal of the NIDDK-sponsored Diabetic Complications Consortium (DiaComp) is to advance the study of diabetic complications and promote communication and collaboration between investigators involved in complications research by supporting scientific meetings and funding new research activities.

DiaComp Pilot and Feasibility Program

This program solicits and funds small Pilot and Feasibility (P&F) projects in high impact areas of diabetic complications research that fall within the primary mission of the NIDDK (please see the NIDDK website for full details). NIDDK complications include diabetic nephropathy, uropathy, neuropathy, neurocognition, gastrointestinal, bone and wound healing. Applications focused on all other diabetic complications (including diabetic retinopathy and cardiovascular disease) do NOT fall within the primary mission of the NIDDK and will be deemed non-responsive. If an application proposes to study multiple diabetic complications, a majority of the proposal must address a DK complication of primary interest.

This program aims to support discovery (hypothesis generating) and innovative (high risk/high reward) research that will advance our understanding of diabetic complications and is increasingly difficult to support through standard NIH mechanisms. Basic, translational and clinical research proposals are encouraged. When appropriate, the use of human samples is strongly encouraged. Research involving human subjects is limited to observational studies with non-invasive or minimally invasive testing and must have IRB approval that includes the collection and use of human samples for research purposes. Interventional clinical trials are beyond the scope of this program.

Awards are expected to prepare the applicant(s) to submit a future investigator- initiated project (e.g. NIH R01). Lower priority will be given to applicants who have received DiaComp support in the past three years.
Applications of 5 pages requesting up to $100,000 for one year are due June 11, 2018.

Current areas of emphasis include, but are not limited to:

New Areas of Interest for 2017 are coming soon.
  • Human Tissue Interrogation
    Develop and use innovative technologies to analyze human tissue from end organs of diabetic complications. For example:

  • Biosensors
    The pathogenesis of diabetic complications is metabolically and genetically complex and involves multiple organ systems. Model organisms are well suited for studying pathophysiology driven or impacted by tissue- and organ-crosstalk. The transparency of C. elegans and zebrafish larvae permits the facile monitoring of cell-based biosensors designed to measure inter- and intra-cellular processes in free living organisms. With the advent of improved genome-editing technologies and large-scale efforts to develop biosensors (e.g. ER stress, oxidative stress, autophagy, glucose levels, hormone levels, albuminuria, etc.), the time is right for researchers to develop novel tools and adapt existing approaches to advance our understanding of the mechanisms underlying diabetic complications. For example:

    Each proposal should indicate how these next generation tools, lines and protocols will be broadly shared.

  • Biofilms
    Biofilms lack a precise definition but are generally accepted to be structured communities of microorganisms, adhered to a surface, and exhibiting phenotypic heterogeneity. Compared to planktonic (free-floating) bacteria, biofilm bacteria are more virulent and resistant to treatment and host immune factors. Biofilms are under-appreciated as a contributor to diabetic complications. For example:

  • Neurocognition
    Emerging data has established a link between insulin resistance, type 2 diabetes, and neurocognitive dysfunction, including dementia (see https://f1000research.com/articles/5-353/v2). For example:

  • Pre-clinical Testing
    There is a compelling need to translate novel, scientifically meritorious therapeutic interventions for diabetic complications. For example:

Budget requests should be commensurate with project needs over a one year project period. While average DiaComp P&F awards are $60,000 Total Costs for one year, well justified requests for support of up to $100,000 Total Costs per year will be considered.

When appropriate, the use of human samples is strongly encouraged, including the linking of human samples to existing tissue repositories and databases (e.g. the NIDDK repository [www.niddkrepository.org/home/] or dkNET [http://www.dknet.org/]). Research involving human subjects is limited to observational studies with non-invasive or minimally invasive testing and must have IRB approval that includes the collection and use of human samples for research purposes.

Interventional clinical trials are beyond the scope of this program.

Streptozotocin (STZ) is used by DiaComp members to induce diabetes in a number of the animal models developed by the consortium. STZ is toxic to the insulin-producing beta cells of the pancreas and used to induce diabetes similar to a type I diabetic patient. Some reports suggest cellular toxicity outside of the pancreas. STZ also exhibits broad spectrum antibacterial properties and alters the gut microbiota. Applicants to DiaComp are reminded to justify their choice of approaches and models of diabetes, including the STZ model, to ensure that appropriate controls are included in all studies and to consider use of complementary approaches. Reviewers are asked to accept use of appropriately justified STZ-diabetes models with appropriate controls unless they can provide direct evidence that the model is inappropriate for the proposed studies.

Applications are due June 11, 2018 for October start dates.

For instructions on how to submit a Pilot & Feasibility Funding Program Application to the DiaComp web portal please click the following link: Funding Program Application Submission Basic Training (PDF)

Back to Top


Applicants may request up to $60,000 (direct + indirect costs) Total Costs for one year or well justified requests for support of up to $100,000. A narrative justification should be provided only for any major equipment (cost greater than $5,000) deemed to be necessary for the proposed project. The number of awards will depend upon the number, quality, duration, and cost of the applications received.

Awards will be made as subcontracts from the DiaComp Coordinating and Bioinformatics Unit (CBU) at Augusta University and not directly by the NIH. Funded awards are not allowed to submit a competitive renewal application and unfunded applications are not allowed to revise and resubmit an amended application. Multi-year funding requests are not allowed.

Back to Top


Each application will receive a primary review by multiple external referees and be given scores for Significance, Investigator, Innovation, Approach, Environment and an Overall Score based on the NIH Scoring System for Research Applications. Scores will range from 1 to 9, where a score of 1-3 indicates an application addressing a problem of high importance/interest in the field and may have some or no weaknesses. A score of 4-6 may be addressing a problem of high importance in the field, but weaknesses in the criteria bring down the overall impact to medium. A score of 7-9 may be addressing a problem of moderate/high importance in the field, but weaknesses in the criteria bring down the overall impact to low. A score of 9 indicates an application with serious and substantive weaknesses with very few strengths. A score of 5 is considered an average score. The entire scale (1-9) should always be considered. Please note that the Overall Score is NOT an average of the other scores. Reviewers will strongly consider the goal of the program to support discovery (hypothesis generating) and innovative (high risk/high reward) research. The DiaComp External Evaluation Committee (EEC) will provide a secondary review of all applications. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed. No additional materials may be submitted after the receipt date. Scientists from the applicant institution are in conflict and excluded from review. Written comments will be provided for all reviewed applications. Final funding decisions will be made by the NIH. All decisions are final and appeals will not be accepted for applications submitted in response to this solicitation. Funded awards are not allowed to submit a competitive renewal application and unfunded applications are not allowed to revise and resubmit an amended application. Multi-year funding requests are not allowed.

Back to Top


January 12, 2018 RFA for DiaComp Pilot Projects is posted on DiaComp website, MMPC and other related websites, and notification of the postings is sent to all US academic and research institutions.
June 11, 2018 Grants Submitted to CBU (Dr. Richard McIndoe, CA 4127, Augusta University, Augusta, Georgia, 30912)
October 2018 Projected start date for DiaComp Pilot Project Funding

Back to Top


The application is the standard PHS 398 form including face, abstract, detailed budget, Biosketch (up to 5 pages), and research plan. The research plan (Sections A-D are limited to 5 pages) should include the following sections:

  1. Specific Aims,
  2. Background and Significance,
  3. Preliminary Studies,
  4. Research Design and Methods,
  5. Literature Cited,
  6. Vertebrate Animals
  7. Sharing Plan

All applications must be submitted via the DiaComp website (PDF format only please).

Eligible Project Directors/Principal Investigators: Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. New investigators are encouraged to apply, but they must have a full-time faculty position or an equivalent position at non-academic institutions.

Eligible Organizations: Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Non-domestic (non-U.S.) Entity; Small Business; For-Profit Organization (Other than Small Business); State Government; Regional Organization; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Eligible agencies of the Federal government; Faith-based or community based organizations.

International institutions and organizations are eligible for support.

Back to Top


Please note that projects devoted to the development of new techniques and tests for the metabolic characterization of mice are NOT responsive to this announcement and are better suited for the MMPC Pilot and Feasibility Grant Program (please see www.mmpc.org for more details). In brief, this program supports applications to:

  • Develop new technologies or miniaturization of existing technologies for use in mice,
  • Develop applications of existing technologies for use in mice,
  • Provide new tests to meet identifiable, outstanding needs necessary to phenotype mouse models of metabolic disease, and
  • Establish new types of mathematical models, informatics, databases or products that augment the mission of the center.


When appropriate, the use of human samples is strongly encouraged, including the linking of human samples to existing tissue repositories and databases (e.g. the NIDDK repository [www.niddkrepository.org/home/] or dkNET [http://www.dknet.org/]). Research involving human subjects is limited to observational studies with non-invasive or minimally invasive testing and must have IRB approval that includes the collection and use of human samples for research purposes. Interventional clinical trials are beyond the scope of this program.

A summary of progress of funded projects is due two months following the completion of the funding period.

DiaComp awardees must follow NIH and HHS policies regarding the sharing of data and resources with the scientific community (http://grants.nih.gov/grants/sharing.htm) and agree to submit to the DiaComp web portal all data and resources resulting from the execution of the awarded application. Data and resources may include, but are not limited to:

  • histology images,
  • protocols,
  • experimental data,
  • RNAseq, and
  • progress report(s).

All data and resources generated with DiaComp support will be made immediately available to "active" DiaComp awardees (see below) and publicly available on the DiaComp website: (1) at the time of first publication, or (2) one year after the award ends. Under certain circumstances, investigators may request an exception to the DiaComp public release policy by contacting NIH Program staff and requesting a waiver. Such requests will be reviewed on a case-by-case basis and waivers will be granted only with sufficient and compelling prior justification.

DiaComp awardees are considered "active" and granted full access to the DiaComp website as members of the DiaComp "Steering Committee" for the duration of their funding period plus 4 years. Outgoing awardees may request an extension from NIH Program staff beyond this "active" period.

Proprietary data and resources will be excluded from sharing consistent with NIH and HHS policies (http://grants.nih.gov/grants/sharing.htm).

Financial acknowledgment of award: Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium (DiaComp) using the following text: 'Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255'.

For presentations and slides, please use the PowerPoint slide with the funding source logo found in the zip file here - http://diacomp.org/images/diacomp-logos.zip - to indicate that DiaComp is a funding source for your presentation.

Back to Top


Richard McIndoe, Ph.D. (Coordinator)
Coordinating and Bioinformatics Unit
Augusta University
Center for Biotechnology and Genomic Medicine
1120 15th Street, CA4124
Augusta, GA 30912-4810
Phone: 706-721-3542
Fax: 706-721-3688

Back to Top